Compare JRI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JRI | NMRA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.8M | 302.0M |
| IPO Year | N/A | 2023 |
| Metric | JRI | NMRA |
|---|---|---|
| Price | $11.62 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 140.3K | ★ 749.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.67 | $0.83 |
| 52 Week High | $14.37 | $3.65 |
| Indicator | JRI | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 23.60 |
| Support Level | $11.67 | $0.83 |
| Resistance Level | $13.11 | $1.74 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 11.76 | 1.61 |
Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.